Yes, prucalopride can cause diarrhea even in patients without constipation
Prucalopride is a selective 5-HT4 receptor agonist that stimulates colonic motility and secretions through its mechanism of action, making diarrhea a predictable adverse effect regardless of baseline constipation status. The drug's pharmacodynamic effects on the gastrointestinal tract do not discriminate based on whether constipation is present.
Evidence from Clinical Trials and FDA Labeling
In clinical trials of patients with chronic idiopathic constipation, diarrhea occurred in 13% of patients taking prucalopride 2 mg daily versus 5% on placebo 1. Importantly:
- 70% of diarrhea cases occurred within the first week of treatment 1
- The diarrhea typically resolved within a few days in 73% of affected patients 1
- Severe diarrhea was reported in 1.8% of prucalopride-treated patients 1
- 1% of patients discontinued treatment specifically due to diarrhea 1
The FDA label explicitly states that overdose may result in exaggeration of known pharmacodynamic effects including diarrhea 1, confirming this is a dose-dependent, mechanism-based effect rather than one dependent on underlying constipation.
Mechanism-Based Risk
Prucalopride works by stimulating high-amplitude propagated contractions in the colon and increasing intestinal secretions 2. These effects occur through 5-HT4 receptor activation regardless of baseline bowel function. In a patient without constipation, these prokinetic and secretory effects would logically increase the risk of diarrhea beyond what was observed in constipated patients.
Clinical Implications
If prucalopride is inadvertently used in a patient without constipation, expect a higher incidence and potentially greater severity of diarrhea than the 13% reported in clinical trials. The drug is contraindicated in patients with intestinal perforation, obstruction, Crohn's disease, ulcerative colitis, and toxic megacolon 1, but these contraindications relate to structural/inflammatory conditions rather than baseline bowel frequency.
Key Monitoring Points:
- Diarrhea onset is typically within the first week 1
- Monitor for fluid and electrolyte disturbances if diarrhea occurs 1
- The effect should resolve within days of discontinuation given the drug's mechanism 1
The bottom line: Prucalopride's mechanism of enhancing GI motility and secretions makes diarrhea an expected adverse effect in any patient, with potentially greater risk in those without baseline constipation who lack the "buffer" of slow transit time.